ライフサイエンスコーパス: uremic

1 n oxidation status between HDL isolated from uremic and healthy patients.

2 pathways were similarly upregulated in both uremic and nonuremic animals after an IPC stimulus.

3 ioprotection after IPC was performed in both uremic and nonuremic animals.

4 Parathyroids from uremic and normal rats segregated on the basis of their

5 g stress factors, including proinflammatory, uremic, and disordered metabolic conditions.

6 Myocardial infarct size was increased in uremic animals, but all 3 conditioning strategies (IPC,

7 identification of risk factors for calcific uremic arteriolopathy (CUA) is necessary to develop prev

8 ular access and progressive hypotension from uremic autonomic dysfunction.

9 ermine the mechanisms of AMC, mice were made uremic by partial right-side renal ablation (week 0), fo

10 the terms "calciphylaxis and warfarin," "non-uremic calciphylaxis," and "nonuremic calciphylaxis." We

11 essing echocardiographic technique to detect uremic cardiomyopathy and predict cardiovascular mortali

12 utine echocardiography in early detection of uremic cardiomyopathy in animal models and whether it pr

13 amplification might ameliorate experimental uremic cardiomyopathy induced by partial nephrectomy (PN

14 istration of pNaKtide after the induction of uremic cardiomyopathy reversed many of the phenotypical

15 acking echocardiography in two rat models of uremic cardiomyopathy soon (4-6 weeks) after induction o

16 iac death and recurrent heart failure due to uremic cardiomyopathy.

17 er correlations with histologic hallmarks of uremic cardiomyopathy.

18 the development of phenotypical features of uremic cardiomyopathy.

19 nd biochemical changes consistent with human uremic cardiomyopathy.

20 st functional deteriorations were related to uremic cardiovascular disease and kidney damage.

21 ding volume overload, electrolyte disorders, uremic complications, and drug toxicity.

22 However, five solutes had uremic concentrations less than 10% of the originally re

23 Furthermore, the uremic concentrations of four solutes did not exceed the

24 esults, more recent articles reported higher uremic concentrations of many solutes, including carboxy

25 remic retention solutes and their normal and uremic concentrations, and it should aid the design of e

26 serum PTH and FGF23 significantly less than uremic controls.

27 ssive daily dialysis can reverse many of the uremic derangements.

28 Uremic dysbiosis and intestinal barrier dysfunction may

29 reased cholesterol efflux to both normal and uremic HDL.

30 at can mimic mental health problems, such as uremic, hepatic, or hypoxic encephalopathy, should be id

31 to increase FGF23 expression as observed in uremic KL(fl/fl) mice.

32 or CD14 reduced the profibrotic responses of uremic leukocytes to endogenous components present in th

33 effects of acute and continuous exposure to uremic levels of indoxylsulfate (IS), p-cresylsulfate (p

34 independently and synergistically regulating uremic metabolism.

35 metabolic profiling to identify and validate uremic metabolites associated with impairment in executi

36 Retention of uremic metabolites is a proposed cause of cognitive impa

37 Uremic metabolites, some of which are anorexigenic and m

38 y to the internal jugular vein in normal and uremic mice and compared these findings with those in fa

39 Uremic mice exhibited high turnover renal osteodystrophy

40 e necessary and sufficient to promote AMC in uremic mice fed a high-phosphate diet, whereas elastin d

41 with wild-type uremic mice, Npt2b-deficient uremic mice had significantly lower levels of serum phos

42 Compared with wild-type mice, normal, or uremic mice lacking Cyp27b1 had lower levels of serum FG

43 because elastin degradation occurred also in uremic mice on a normal-phosphate diet, but they did not

44 Endothelial cells (ECs) of AVFs in uremic mice or patients expressed mesenchymal markers (F

45 To address this, calcified aortas from uremic mice were transplanted orthotopically into normal

46 Compared with wild-type uremic mice, Npt2b-deficient uremic mice had significant

47 tch target genes increased in ECs of AVFs in uremic mice.

48 The uremic milieu is profoundly thrombogenic and upregulates

49 The uremic milieu provides a perfect storm of risk factors f

50 nflammatory activities that are defective in uremic patients as a result of specific changes in its m

51 o the analyses of 15 healthy subjects and 24 uremic patients undergoing hemodialysis.

52 ion (AMC), a hallmark of vascular disease in uremic patients, is highly correlated with serum phospha

53 ve role in the increased ST risk observed in uremic patients.

54 oneal dialysis effluent (PDE) of noninfected uremic patients.

55 Compared with long-term PD control and uremic peritoneum, EPS peritoneum showed thicker submeso

56 Uremic plasma (10%) was added to cultures of neonatal Sp

57 sociated with morbidity and mortality in non-uremic populations, ScvO2 has received little attention

58 Moreover, uremic PT-Dicer(-/-) mice increased serum PTH and FGF23

59 sulfate and p-cresyl sulfate remained in the uremic range.

60 ary hyperparathyroidism rats and in vitro in uremic rat parathyroid glands in organ culture.

61 prevented the increase in serum PTH level in uremic rats and decreased levels of secreted PTH in para

62 controls and uremic rats fed a normal diet, uremic rats fed a high-phosphorous diet had lower levels

63 Compared with controls and uremic rats fed a normal diet, uremic rats fed a high-ph

64 of the 11betaHSD inhibitor carbenoxolone to uremic rats for 2 wk improved glucose tolerance and insu

65 tho and FGF receptor (FEFR)-1 in healthy and uremic rats induced by 5/6 nephrectomy.

66 Uremic rats on a high-phosphate (HP) diet presented hype

67 hyroid hormone (PTH) secretion in normal and uremic rats, as well as in mouse parathyroid organ cultu

68 tion of renal Klotho and FGFR1 in normal and uremic rats.

69 e colonic microbiota as a relevant source of uremic retention solutes accumulating in CKD.

70 y, this review extends the classification of uremic retention solutes and their normal and uremic con

71 ports a biologic effect of the protein-bound uremic retention solutes indoxyl sulfate and p-cresyl su

72 tal in vitro data link several protein-bound uremic retention solutes to the modulation of inflammato

73 though they had been previously described as uremic retention solutes.

74 Uremic rpS6(p-/-) mice had no increase in parathyroid ce

75 Uremic sera induced 2- to 3-fold higher TF expression an

76 smooth muscle cells (vSMCs) pretreated with uremic serum (obtained from ESRD patients on hemodialysi

77 o in vitro models of vascular calcification (uremic serum and high-calcium and -phosphorus medium), a

78 d significantly greater clot formation after uremic serum exposure, which was substantially reduced w

79 were examined after vSMCs were treated with uremic serum or solutes.

80 ndergoes ubiquitination at baseline and that uremic serum, indole-3-acetic acid, and indoxyl sulfate

81 We investigated whether the uremic solute indole-3 acetic acid (IAA) predicts clinic

82 bial metabolism substantially contributes to uremic solute production.

83 chexia, hypertension, diabetes, proteinuria, uremic solute retention, anemia, and repeated subclinica

84 es of OAT1 and OAT3 in the regulation of the uremic solutes and supports the centrality of these "dru

85 In CKD, uremic solutes may induce endothelial dysfunction, infla

86 reatment used lowered plasma levels of small uremic solutes other than urea.

87 duce vSMC TF may help to prevent ST and that uremic solutes should be considered as novel risk factor

88 Relevant concentrations of isolated uremic solutes such as indole-3-acetic acid (3.5 mug/mL)

89 microbes may produce an important portion of uremic solutes, most of which remain unidentified.

90 l subjects, suggesting that they represented uremic solutes.

91 ntify and further characterize colon-derived uremic solutes.

92 nyl standards to identify five colon-derived uremic solutes: alpha-phenylacetyl-l-glutamine, 5-hydrox

93 Despite their uremic state, the D25V-carriers exhibit low triglyceride

94 y UF attenuates sleep apnea without altering uremic status.

95 alysis fluid exposure under either normal or uremic status.

96 y efficient metabolic machinery to alleviate uremic symptoms.

97 ve been reported--3167 without the hemolytic-uremic syndrome (16 deaths) and 908 with the hemolytic-u

98 drome (16 deaths) and 908 with the hemolytic-uremic syndrome (34 deaths)--indicating that this strain

99 Complement mediated hemolytic uremic syndrome (aHUS) accounts for a significant propor

100 ns predispose patients to atypical hemolytic uremic syndrome (aHUS) and other disorders arising from

101 causally associated with atypical hemolytic uremic syndrome (aHUS) and related glomerulopathies.

102 therapy in patients with atypical hemolytic uremic syndrome (aHUS) are remarkable in contrast to the

103 een well characterized in atypical hemolytic uremic syndrome (aHUS) but have been less well described

104 Patients with atypical hemolytic uremic syndrome (aHUS) develop a thrombotic microangiopa

105 assay that could convert atypical hemolytic uremic syndrome (aHUS) from a diagnosis of exclusion int

106 shares similarities with atypical hemolytic uremic syndrome (aHUS) in the underlying pathomechanisms

107 Atypical hemolytic uremic syndrome (aHUS) is a genetic ultrarare renal dise

108 Atypical hemolytic uremic syndrome (aHUS) is a genetic, life-threatening di

109 Atypical hemolytic uremic syndrome (aHUS) is a rare disease with a high rec

110 Atypical hemolytic uremic syndrome (aHUS) is a rare renal thrombotic microa

111 Atypical hemolytic uremic syndrome (aHUS) is a renal disease associated wit

112 Atypical hemolytic uremic syndrome (aHUS) is a severe thrombotic microangio

113 Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (

114 Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy c

115 Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy w

116 Atypical hemolytic uremic syndrome (aHUS) is an orphan disease with a high

117 Atypical hemolytic-uremic syndrome (aHUS) is associated with genetic comple

118 Atypical hemolytic uremic syndrome (aHUS) is characterized by complement at

119 Atypical hemolytic uremic syndrome (aHUS) is characterized by dysregulated

120 Atypical hemolytic uremic syndrome (aHUS) is characterized by genetic and a

121 Atypical hemolytic uremic syndrome (aHUS) is classically described to resul

122 The pathogenesis of atypical hemolytic uremic syndrome (aHUS) is strongly linked to dysregulati

123 Atypical hemolytic uremic syndrome (aHUS) is usually characterized by uncon

124 mplement C3 identified in atypical hemolytic uremic syndrome (aHUS) patients cause dysregulation in t

125 tic microangiopathy (TMA) atypical hemolytic uremic syndrome (aHUS) resulted in the successful introd

126 glomerulopathy (C3G) and atypical hemolytic uremic syndrome (aHUS) strongly associate with inherited

127 escribed in patients with atypical hemolytic uremic syndrome (aHUS), a rare condition characterized b

128 Atypical hemolytic uremic syndrome (aHUS), a rare form of thrombotic microa

129 ribed in association with atypical hemolytic uremic syndrome (aHUS), also confers high risk of age-re

130 reportedly contribute to atypical hemolytic uremic syndrome (aHUS), but incomplete penetrance sugges

131 ereas R53H-CFH, linked to atypical hemolytic uremic syndrome (aHUS), was defective in C3bBb decay-acc

132 nt dysregulation leads to atypical hemolytic uremic syndrome (aHUS), while ADAMTS13 deficiency causes

133 ngiopathy (TMA), known as atypical hemolytic uremic syndrome (aHUS).

134 she developed postpartum atypical hemolytic uremic syndrome (aHUS).

135 hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

136 al to the pathogenesis of atypical hemolytic uremic syndrome (aHUS).

137 Diarrhea-associated hemolytic uremic syndrome (D(+)HUS) is caused by the ingestion of

138 ia coli causes diarrhea-associated hemolytic-uremic syndrome (DHUS), a severe renal thrombotic microa

139 42 cases, including 855 cases with hemolytic uremic syndrome (HUS) and 53 deaths.

140 x2) responsible for development of hemolytic uremic syndrome (HUS) and acute kidney injury (AKI).

141 histomorphologic similarities with hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic pu

142 thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are appropriately at the top of a

143 Hemolytic uremic syndrome (HUS) caused by intestinal Shiga toxin-p

144 Hemolytic-uremic syndrome (HUS) features episodes of small-vessel

145 rhea or developed life-threatening hemolytic uremic syndrome (HUS) in any of 6 closed cohorts from 4

146 sed an outbreak with >800 cases of hemolytic uremic syndrome (HUS) in Germany, including 90 children.

147 Hemolytic uremic syndrome (HUS) is a potentially life-threatening

148 Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy ch

149 Hemolytic-uremic syndrome (HUS) is a thrombotic microangiopathy th

150 scherichia coli O157:H7-associated hemolytic-uremic syndrome (HUS) is characterized by profound proth

151 Hemolytic uremic syndrome (HUS) is the life-threatenig sequela of

152 Postdiarrheal hemolytic uremic syndrome (HUS) is the most common cause of acute

153 Hemolytic uremic syndrome (HUS) occurred in 12 patients (10 infect

154 infection with a high incidence of hemolytic uremic syndrome (HUS) occurred in Germany in May 2011.

155 2011 the largest known outbreak of hemolytic uremic syndrome (HUS) occurred in northern Germany.

156 On 22 June 2011, 8 patients with hemolytic uremic syndrome (HUS) or bloody diarrhea were reported i

157 the 62 individuals with diarrheal hemolytic uremic syndrome (HUS) seen at our institution during the

158 g agent of postdiarrhea-associated hemolytic uremic syndrome (HUS), a disorder of glomerular ischemic

159 imary cause of diarrhea-associated hemolytic uremic syndrome (HUS), a disorder of thrombocytopenia, m

160 main etiological agent that causes hemolytic uremic syndrome (HUS), a microangiopathic disease charac

161 cytotoxic proteins that can cause hemolytic-uremic syndrome (HUS), a thrombotic microangiopathy, fol

162 s, the development and severity of hemolytic uremic syndrome (HUS), and adverse outcomes in STEC-infe

163 Hemolytic-uremic syndrome (HUS), caused by Shiga toxin (Stx)-produ

164 es to hemorrhagic colitis (HC) and hemolytic uremic syndrome (HUS), due to the expression of one or m

165 e pathogenesis of postenteropathic hemolytic uremic syndrome (HUS), most commonly caused by Shiga tox

166 complicated by potentially lethal hemolytic uremic syndrome (HUS), particularly in children.

167 h as sickle cell disease (SCD) and hemolytic uremic syndrome (HUS), pathological biophysical interact

168 b pasudotox for 10 doses developed hemolytic uremic syndrome (HUS), thrombotic microangiopathy (TMA),

169 uding hemorrhagic colitis (HC) and hemolytic-uremic syndrome (HUS), which is the most common cause of

170 outcomes of waitlisted adults with hemolytic uremic syndrome (HUS).

171 cing Escherichia coli (STEC) cause hemolytic uremic syndrome (HUS).

172 kidney-damaging sequela called the hemolytic uremic syndrome (HUS).

173 causes hemorrhagic colitis and the hemolytic-uremic syndrome (HUS).

174 ere hospitalized, including 4 with hemolytic uremic syndrome (HUS).

175 22% of these individuals developed hemolytic-uremic syndrome (HUS).

176 r the serious disease consequence, hemolytic-uremic syndrome (HUS).

177 oli (EHEC) O26 causes diarrhea and hemolytic uremic syndrome (HUS).

178 tery, hemorrhagic colitis (HC) and hemolytic uremic syndrome (HUS).

179 ess and sometimes life-threatening hemolytic uremic syndrome (HUS).

180 li O157:H7 is the leading cause of hemolytic uremic syndrome (HUS).

181 ng-term prognosis of children with hemolytic uremic syndrome (HUS).

182 is associated with development of hemolytic uremic syndrome (HUS).

183 treptococcus pneumoniae associated hemolytic uremic syndrome (SpHUS) is defined by the occurrence of

184 renal diseases, including atypical hemolytic uremic syndrome and C3 glomerulopathies, and age-related

185 d with the renal diseases atypical hemolytic uremic syndrome and dense deposit disease and the ocular

186 The outbreak of hemolytic-uremic syndrome and diarrhea caused by Shiga toxin-produ

187 affected with late-onset atypical hemolytic uremic syndrome and symptoms of glomerulonephritis.

188 iated endothelial damage: atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura.

189 of clinical presentation (atypical hemolytic uremic syndrome as thrombotic microangiopathy), biopsy a

190 n (Stx) causes diarrhea-associated hemolytic uremic syndrome by damaging renal microvascular endothel

191 large outbreak of diarrhea and the hemolytic-uremic syndrome caused by an unusual serotype of Shiga-t

192 nticomplement therapy for atypical hemolytic uremic syndrome during pregnancy, and implications of th

193 toxin-producing E. coli-associated hemolytic uremic syndrome during this outbreak.

194 e have identified a large atypical hemolytic uremic syndrome family where a deletion has occurred thr

195 Atypical hemolytic uremic syndrome has been associated with dysregulation o

196 We report a case of hemolytic uremic syndrome in a 69-year-old woman due to Shiga toxi

197 TEC) O146:H28 infection leading to hemolytic uremic syndrome in a neonate.

198 diarrhea, hemorrhagic colitis, and hemolytic uremic syndrome in humans.

199 toxin-producing E. coli-associated hemolytic uremic syndrome in six hospitals in Hamburg, Germany, be

200 s can trigger episodes of atypical hemolytic uremic syndrome in susceptible patients.

201 Hemolytic uremic syndrome is a disease characterized by hemolytic

202 Atypical hemolytic-uremic syndrome is a genetic, life-threatening, chronic

203 and autoantibody-positive form of hemolytic uremic syndrome is characterized by the presence of auto

204 ife-threatening sequela called the hemolytic uremic syndrome is unpredictable.

205 a coli serotype O104:H4-associated hemolytic uremic syndrome occurred in Northern Germany.

206 toxin-producing E. coli-associated hemolytic uremic syndrome outbreak in Germany, critical illness de

207 om 19 anti-FH Ab-positive atypical hemolytic uremic syndrome patients collected at the acute phase of

208 en that causes bloody diarrhea and hemolytic uremic syndrome throughout the world.

209 toxin-producing E. coli-associated hemolytic uremic syndrome were admitted to eight ICUs.

210 ls in which patients with atypical hemolytic-uremic syndrome who were 12 years of age or older receiv

211 In hemolytic uremic syndrome with brain involvement symptoms develop

212 ormalities consistent with grade 2 hemolytic uremic syndrome with peak creatinine of 1.53 to 1.66 mg/

213 ks of gastrointestinal illness and hemolytic uremic syndrome worldwide.

214 esponsible for bloody diarrhea and hemolytic-uremic syndrome worldwide.

215 ive regulation of the AP (atypical hemolytic-uremic syndrome) or with inadequate cleavage by ADAMTS-1

216 The Oklahoma TTP-HUS (hemolytic uremic syndrome) Registry enrolled 70 consecutive patien

217 Hemolytic uremic syndrome, a life-threatening disease often accomp

218 FH and MCP are linked to atypical hemolytic uremic syndrome, a type of thrombotic microangiopathy (T

219 ted macular degeneration, atypical hemolytic uremic syndrome, and C3 glomerulopathies.

220 implicated previously in atypical hemolytic uremic syndrome, and it abrogates C-terminal ligand bind

221 diseases such as AMD and atypical hemolytic uremic syndrome, and leads to a better understanding of

222 35 were hospitalized, 10 developed hemolytic-uremic syndrome, and none died.

223 sses, such as hemorrhagic colitis, hemolytic uremic syndrome, and septicemia.

224 emic lupus erythematosus, atypical hemolytic uremic syndrome, and the complocentric membranoglomerulo

225 es have been described in atypical hemolytic uremic syndrome, arising commonly through nonallelic hom

226 hemoglobinuria (PNH) and atypical hemolytic uremic syndrome, blocks the terminal complement pathway

227 croangiopathies including atypical hemolytic uremic syndrome, C3 and C1q glomerulopathies, and preecl

228 botic thrombocytopenic purpura and hemolytic-uremic syndrome, have been reported to have a drug-induc

229 tients with the autoimmune form of hemolytic uremic syndrome, is involved in B cell regulation.

230 O157:H7 can cause bloody diarrhea, hemolytic uremic syndrome, or even death.

231 of rare diseases such as atypical hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, C3

232 d with wild type FH19-20, atypical hemolytic uremic syndrome-associated mutants were less able to com

233 ve or therapeutic ends, for use in hemolytic uremic syndrome-endemic areas or during future outbreaks

234 en causing hemorrhagic colitis and hemolytic uremic syndrome.

235 and disseminated malignancy or in hemolytic uremic syndrome.

236 litis that sometimes progresses to hemolytic-uremic syndrome.

237 izumab after a relapse of atypical hemolytic uremic syndrome.

238 erleukin-1beta, has been linked to hemolytic uremic syndrome.

239 y sera from patients with atypical hemolytic uremic syndrome.

240 hat causes hemorrhagic colitis and hemolytic uremic syndrome.

241 an experimental model for atypical hemolytic uremic syndrome.

242 O157 strains (P = 0.03) developing hemolytic-uremic syndrome.

243 ology of neuronal complications in hemolytic-uremic syndrome.

244 function in patients with atypical hemolytic-uremic syndrome.

245 evelopment of the life-threatening hemolytic uremic syndrome.

246 nsidered in the workup of neonatal hemolytic uremic syndrome.

247 ienced fatal chronic rejection and hemolytic uremic syndrome.

248 kinase epsilon result in atypical hemolytic-uremic syndrome.

249 c thrombocytopenic purpura and the hemolytic uremic syndrome.

250 causes severe bloody diarrhea and hemolytic uremic syndrome.

251 ar degeneration (AMD) and atypical hemolytic uremic syndrome.

252 r and renal injury and can trigger hemolytic uremic syndrome.

253 re hospitalized and 6.4% developed hemolytic uremic syndrome.

254 renal diseases, including atypical hemolytic uremic syndrome.

255 ribed in association with atypical hemolytic uremic syndrome.

256 hagic colitis and life-threatening hemolytic uremic syndrome.

257 es such as hemorrhagic colitis and hemolytic-uremic syndrome.

258 microangiopathy disease, atypical hemolytic uremic syndrome.

259 ers' diarrhea, gastroenteritis and hemolytic uremic syndrome.

260 re clinical manifestations such as hemolytic-uremic syndrome.

261 (EHEC) causes bloody diarrhea and hemolytic-uremic syndrome.

262 mbomicroangiopathy called atypical hemolytic uremic syndrome.

263 turnal hemoglobinuria and atypical hemolytic uremic syndrome.

264 ings in a four-month-old male with hemolytic uremic syndrome.

265 sy of a child with EHEC-associated hemolytic uremic syndrome.

266 luding hemorrhagic colitis and the hemolytic uremic syndrome.

267 s the cause of bloody diarrhea and hemolytic-uremic syndrome.

268 infections, as well as sepsis and hemolytic uremic syndrome.

269 s, such as hemorrhagic colitis and hemolytic uremic syndrome.

270 nditioning) appeared to be more effective in uremic than in sham (nonuremic) animals.

271 terature search and found 621 articles about uremic toxicity published after a 2003 review of this to

272 e systemic circulation, which contributes to uremic toxicity, inflammation, progression of CKD, and a

273 emodialysis, although beneficial in terms of uremic toxin clearance, also contributes to cognitive de

274 We tested whether the uremic toxin indoxyl sulfate (IS), an endogenous ligand

275 icrobiome and demonstrate that levels of the uremic toxin indoxyl sulfate can be modulated in vivo by

276 The highly protein-bound uremic toxin indoxyl sulfate has emerged as a potent tox

277 d is p-cresyl sulfate (PCS), a protein-bound uremic toxin that originates from tyrosine metabolism by

278 uggest that indoxyl sulfate, a protein-bound uremic toxin, may induce vascular dysfunction and thromb

279 of resistin, a proinflammatory cytokine and uremic toxin, were significantly elevated during both fo

280 Protein-bound uremic toxins (PBUTs) are difficult to remove by convent

281 acid, gut microbiome products, and so-called uremic toxins accumulating in chronic kidney disease.

282 These records described 32 previously known uremic toxins and 56 newly reported solutes.

283 kidney proximal tubule (PT) transporters of uremic toxins and solutes (e.g., indoxyl sulfate, p-cres

284 OAT1 and/or OAT3 in the handling of over 35 uremic toxins and solutes, including those derived from

285 rogram suggested that increased clearance of uremic toxins by intensified hemodialysis improves pregn

286 Uremic toxins could modify the expression and/or activit

287 d review of the existing knowledge regarding uremic toxins facilitates the design of experimental stu

288 bacterial endotoxins, or adsorb gut-derived uremic toxins have been developed.

289 Accumulation of uremic toxins is a hallmark of renal excretory dysfuncti

290 is review, we demonstrate that protein-bound uremic toxins may play an important role in progression

291 However, the impact of these uremic toxins on the crosstalk between endothelium and l

292 P and history of cardiovascular disease; and uremic toxins p-cresyl sulfate and indoxyl sulfate.

293 s (including tryptophan-derivatives that are uremic toxins), and lipids.

294 hanisms, including direct neuronal injury by uremic toxins, could also be involved, especially in the

295 In CKD, uremic toxins, hyperparathyroidism and Klotho deficiency

296 Emerging evidence suggests that uremic toxins, in particular indoxyl sulfate (IS) and p-

297 Altogether, these results suggest that uremic toxins, such as IS, through effects on drug trans

298 excreted by the kidneys, which are potential uremic toxins.

299 Uremic wild-type (KL(fl/fl) ) and knockout (Prx1-Cre;KL(

300 iferation compared with a marked increase in uremic wild-type mice.